Novavax said Monday morning that the Food and Drug Administration was asking the company to run a new trial of its Covid-19 ...

Analysis found 25% tariff on pharmaceutical imports would hike U.S. drug costs by nearly $51 billion annually, boosting ...

Novavax’s COVID-19 vaccine could soon receive full approval from the United States Food and Drug Administration.

Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...

The FDA, which was supposed to decide by April 1 whether it would approve Novavax's application for a full license, is seeking more clinical studies of the vaccine. Now, because other drugmakers ...

Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

After a 20% cut to the FDA’s workforce, biotechs and pharmas are bracing for delays. But the impacts won’t be consistent.

Takeda, a Japanese pharmaceutical company, plans to launch its dengue vaccine, Qdenga, in India next year in collaboration with Biological E. Clinical trials are underway, and the company aims to ...

A study published last week suggests that, if vaccine uptake continues to decline, measles will soon be endemic again in the ...

A summary of current health news, including the disbanding of a U.S. Justice Department unit focusing on food and drug safety ...